CRYSTALLINE FORMS OF THERAPEUTIC COMPOUNDS AND USES THEREOF
Described herein are crystalline forms of Compound 1 useful for the prevention and treatment of angiogenic ocular conditions; methods of treating a disease comprising; processes for preparing; and kits comprising, the same.
1 . A method of inhibiting aberrant signaling of a growth factor comprising administering to a subject a therapeutically effective amount of a crystalline form of Compound 1:
wherein the crystalline form has an XRPD pattern comprising peaks at 7-8 degrees 2θ, 12.5-13.5 degrees 2θ, 14.5-15.5 degrees 2θ, 17-18 degrees 2θ, and 26-27 degrees 2θ, or
a pharmaceutical composition comprising the crystalline form.
2 . The method of claim 1 , wherein the growth factor is vascular endothelial growth factor.
3 . The method of claim 2 , wherein aberrant signaling of a growth factor is associated with a disease selected from cancer, a benign neoplasm, atherosclerosis, hypertension, an inflammatory disease, rheumatoid arthritis, and an ocular disease.
4 . The method of claim 1 , wherein the crystalline form is a hydrate.
5 . The method of claim 1 , wherein the pharmaceutical composition is suitable for topical administration.
6 . The method of claim 3 , wherein the ocular disease is macular edema.
7 . The method of claim 6 , wherein the ocular disease is a diabetic macular edema or cystoid macular edema.
8 . The method of claim 7 , wherein the ocular disease is a macular degeneration.
9 . The method of claim 3 , wherein the ocular disease is a retinal vein occlusion.
10 . The method of claim 3 , wherein the ocular disease is retinopathy.
11 . The method of claim 8 , wherein the ocular disease is age-related macular degeneration (AMD).
12 . The method of claim 3 , wherein the ocular disease is corneal neovascularization.
13 . The method of claim 3 , wherein the ocular disease is glaucoma.
14 . The method of claim 3 , wherein the ocular disease is inflammatory meibomian gland disease.
15 . The method of claim 3 , wherein the ocular disease is dry eye syndrome.
16 . The method of claim 3 , wherein the ocular disease is blepharitis.
17 . The method of claim 3 , wherein the ocular disease is uveitis.
18 . The method of claim 3 , wherein the ocular disease is allergic conjunctivitis.
19 . The method of claim 3 , wherein the ocular disease is rosacea of the eye.
20 . A kit comprising a crystalline form of Compound 1:
wherein the crystalline form has an X-ray powder diffraction (XRPD) pattern comprising peaks at 7-8 degrees 2θ, 12.5-13.5 degrees 2θ, 14.5-15.5 degrees 2θ, 17-18 degrees 2θ, and 26-27 degrees 2θ, or
a pharmaceutical composition comprising the crystalline form.